Effect of coenzyme Q10 on the survival time and lipid peroxidation of adriamycin (doxorubicin) treated mice.

Shinya Shinozawa*  Kouhei Etowo†
Yasunori Araki‡  Takuzo Oda**
Effect of coenzyme Q10 on the survival time and lipid peroxidation of adriamycin (doxorubicin) treated mice.*

Shinya Shinozawa, Kouhei Etowo, Yasunori Araki, and Takuzo Oda

Abstract

The effect of coenzyme Q10 (Co Q10) was examined on the survival time and lipid peroxidation of adriamycin (ADM)-treated ICR mice. Co Q10 showed a protective effect against a subacute toxicity in mice induced by two intraperitoneal administrations of ADM (15 mg/kg). The group treated orally with 10 mg/kg of Co Q10 showed the longest survival time of all the groups studied (16.81 +/- 10.29 days, mean +/- S.D.) and a significantly longer survival time (p less than 0.001) than the ADM-alone group (7.48 +/- 1.99 days). The inhibitory effect of Co Q10 on the plasma and tissue lipid peroxidation levels did not correlate with the effect of prolonging the survival time of mice. Co Q10 tended to inhibit rises in plasma and liver lipid peroxidation levels induced by ADM administration, but there was no statistically significant difference between treatments. There was a statistically significant different inhibitory effect in the kidney lipid peroxidation levels, but was not in those of the heart.

KEYWORDS: coenzymeQ₁₀, adriamycin, doxorubicin, lipid peroxidation, plasma and tissues, toxicity

*PMID: 6702487 [PubMed - indexed for MEDLINE]
Copyright (C) OKAYAMA UNIVERSITY MEDICAL SCHOOL
EFFECT OF COENZYME Q₁₀ ON THE SURVIVAL TIME AND LIPID PEROXIDATION OF ADRIAMYCIN (DOXORUBICIN) TREATED MICE

Shinya SHINOZAWA, Kouhei ETOWO, Yasunori ARAKI and Takuzo ODA*

Department of Hospital Pharmacy, and* Department of Biochemistry, Cancer Institute, Okayama University Medical School, Okayama, 700, Japan

Received September 11, 1983

Abstract. The effect of coenzyme Q₁₀ (Co Q₁₀) was examined on the survival time and lipid peroxidation of adriamycin (ADM)-treated ICR mice. Co Q₁₀ showed a protective effect against a subacute toxicity in mice induced by two intraperitoneal administrations of ADM (15 mg/kg). The group treated orally with 10 mg/kg of Co Q₁₀ showed the longest survival time of all the groups studied (16.81 ± 10.29 days, mean ± S.D.) and a significantly longer survival time (p< 0.001) than the ADM-alone group (7.48 ± 1.99 days). The inhibitory effect of Co Q₁₀ on the plasma and tissue lipid peroxidation levels did not correlate with the effect of prolonging the survival time of mice. Co Q₁₀ tended to inhibit rises in plasma and liver lipid peroxidation levels induced by ADM administration, but there was no statistically significant difference between treatments. There was a statistically significant different inhibitory effect in the kidney lipid peroxidation levels, but was not in those of the heart.

Key words: coenzyme Q₁₀, adriamycin, doxorubicin, lipid peroxidation, plasma and tissues, toxicity.

Adriamycin (ADM), an anthracycline antibiotic, has shown marked activity against a wide range of human neoplasms, but its clinical use has been limited because of the risk of dose-dependent severe toxicity to the liver, kidney, bone marrow and heart (1-3). ADM-induced toxicity has been considered to result from biomembrane damage (4, 5). Therefore, in this paper we report the effect of coenzyme Q₁₀ (Co Q₁₀), which has membrane stabilizing and anti-oxidant activities (6-8), on ADM-induced toxicity.

MATERIALS AND METHODS

Reagents. Adriamycin hydrochloride (Adriacin®, Lot No. 145 A JB) was kindly donated by Kyowa Hakko Co., Ltd. (Tokyo, Japan). Udidecarenone (Co Q₁₀ powder), injectable Co Q₁₀ (Co Q₁₀ E-0216-019) and its solvent (placebo E-0216-119, which contains 1.8 mg phospholipid, 30 mg polyglycol and 45 mg sorbitol/ml of citrate buffer, pH 7.4) were kindly donated by Eisai Co., Ltd. (Tokyo, Japan).

In vivo, survival experiment. Five-week-old male ICR mice (25-30 g body weight) were divided into groups of 10-20 mice each and injected intraperitoneally with ADM solution (2 mg ADM/ml of sterilized saline) at a dose of 15 mg/kg on days 0 and 4. For the Co Q₁₀ solution
groups, mice were administered a Co Q_{10} suspension (1 mg Co Q_{10} /5 ml of 0.5 % carboxymethyl cellulose, CMC solution) orally (p.o.) at doses of 2, 10 and 50 mg/kg. Co Q_{10} E-0216-019 was administered p.o. or injected subcutaneously (s.c.) at doses of 2, 10 and 50 mg/kg into mice of the Co Q_{10} E-0216-019 groups. For the placebo groups (placebo E-0216-119 group) the mice were administered 10 mg/kg E-0216-119 p.o. or injected s.c. with the same at doses of 10 and 50 mg/kg. Co Q_{10}; placebo and saline were all administered to mice from day -3 to 6 once a day, two h before ADM administration (day 0 = day of first ADM administration).

**In vivo, lipid peroxidation experiments.** The animals used and the dosage and method of ADM administration were the same as those used in the survival experiments. Groups of six mice each were administered ADM and saline p.o. (ADM group) or ADM and Co Q_{10} p.o. (Co Q_{10} group) at a dose of 10 mg/kg. From day -1 to day 6, two h after Co Q_{10} or ADM administration, the cervical artery of each mouse was cut at definite intervals. Blood samples were collected in heparinized tubes. Plasma samples were obtained by centrifugation at 2000 × g for 10 min, and the plasma and carcasses were stored at -20°C until measurement. Subsequently, the liver, kidney, spleen and heart of each mouse was excised, washed with a sterilized saline solution and cut into small pieces in a 1.15 % KCl solution. Lastly, the pieces were homogenized with a Polytron homogenizer to make a 10 % homogenate.

**Determination of lipid peroxidation in plasma and tissues.** Determination of lipid peroxidation in plasma was carried out by measuring the formation of 2-thiobarbituric acid (TBA)-reacting substances, supposedly malondialdehyde, using tetraethyloxypropan as the standard material in a fluorophotometric assay (excitation wavelength at 515 nm, emission at 553 nm) described by Yagi (9). The lipid peroxidation in the plasma was expressed as n moles malondialdehyde/ml of plasma. Determination of lipid peroxidation in the tissues was carried out with a photometric assay at 534 nm described by Ohkawa et al. (10), and the lipid peroxidation was expressed as n moles malondialdehyde/g wet wt. The significance of the mean was determined with Student's unpaired tests in all experiments.

**RESULTS**

**Effect of Co Q_{10} on the Survival of ADM-Treated Mice.** After an intraperitoneal injection of ADM at a dose of 15 mg/kg on days 0 and 4, the control mice treated with saline alone (ADM group) survived 7.48 ± 1.99 days (n=54, mean ± S.D.). In this group no mice survived more than 30 days. Mice of the group treated with 10 mg/kg of Co Q_{10} CMC solution (p.o.) survived the longest of all the mice studied (16.81 ± 10.29 days) and survived significantly longer than the mice of the ADM group (p<0.001). Six of the twenty-two mice in the group survived more than 30 days. Most of the groups treated with Co Q_{10} E-0216-019 (except the 2 mg/kg treatment) showed a significantly longer survival time than the ADM group, but not significantly longer than the placebo E-0216-119 groups whose dosage corresponded to each. The placebo E-0216-119 groups showed a significantly longer survival time than the ADM group, as did p.o. group number 11 (p<0.05) and s.c. group number 12 (p<0.001), as shown in Table 1.

**Effect of Co Q_{10} on Lipid Peroxidation in Plasma and Tissues.** The plasma lipid peroxidation in the ADM group was most reactive and showed peak levels on days
Table 1. Effect of Co Q₁₀ on the survival time of ADM-treated ICR mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Co Q₁₀ Dose (mg/kg)</th>
<th>Route</th>
<th>Survival time (mean ± S.D.)</th>
<th>No. of mice surviving 30 days</th>
<th>No. of experiments</th>
<th>Significance against (group No.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ADM + Saline</td>
<td>0</td>
<td>p.o.</td>
<td>7.48 ± 1.99</td>
<td>0</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>2 ADM + Co Q₁₅ sol.</td>
<td>2</td>
<td>p.o.</td>
<td>15.40 ± 10.66</td>
<td>6</td>
<td>22</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>p.o.</td>
<td>16.81 ± 10.29</td>
<td>6</td>
<td>22</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>p.o.</td>
<td>9.45 ± 3.95</td>
<td>0</td>
<td>11</td>
<td>p &lt; 0.02 (1)</td>
</tr>
<tr>
<td>5 ADM + Co Q₁₅ E-0216-019</td>
<td>2</td>
<td>p.o.</td>
<td>7.90 ± 3.14</td>
<td>0</td>
<td>10</td>
<td>N.S.(e)(1), (11)</td>
</tr>
<tr>
<td>6</td>
<td>10</td>
<td>p.o.</td>
<td>14.81 ± 9.68</td>
<td>2</td>
<td>10</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
<td>p.o.</td>
<td>11.30 ± 6.66</td>
<td>0</td>
<td>10</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>s.c.</td>
<td>10.00 ± 6.12</td>
<td>0</td>
<td>10</td>
<td>p &lt; 0.02 (1)</td>
</tr>
<tr>
<td>9</td>
<td>10</td>
<td>s.c.</td>
<td>11.60 ± 8.28</td>
<td>1</td>
<td>10</td>
<td>p &lt; 0.01 (1)</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>s.c.</td>
<td>12.31 ± 9.67</td>
<td>2</td>
<td>16</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>11 ADM + Placebo E-0216-119</td>
<td>0</td>
<td>p.o.</td>
<td>9.40 ± 4.88</td>
<td>0</td>
<td>10</td>
<td>p &lt; 0.05 (1)</td>
</tr>
<tr>
<td>12</td>
<td>0</td>
<td>s.c.</td>
<td>11.70 ± 7.76</td>
<td>1</td>
<td>10</td>
<td>p &lt; 0.001 (1)</td>
</tr>
<tr>
<td>13</td>
<td>0</td>
<td>s.c.</td>
<td>7.70 ± 1.05</td>
<td>0</td>
<td>10</td>
<td>N.S. (1)</td>
</tr>
</tbody>
</table>

* The mice were injected with ADM (15 mg/kg) i.p. on days 0 and 4 with 10 times of the administration of saline, Co Q₁₀ or its placebo (once a day, from day 3 to 6).

b Co Q₁₅ sol.: Ubidecarenone powder in 0.5% carboxymethyl cellulose sol.

c Co Q₁₅ E-0216-019: Injectable Co Q₁₀.

d Not significantly different.

e Placebo E-0216-119: Placebo of Co Q₁₀ E-0216-019 (contains phospholipid 1.8 mg, polyglycol 30 mg and sorbitol 45 mg/ml of citrate buffer, pH 7.4).

{f,g,h} Administered 10 mg/kg placebo E-0216-019 p.o. (f), s.c. (g) and 50 mg/kg s.c. (h).

0, 4 and 6. The Co Q₁₀ group showed inhibition of these rises, but did not show a statistically significant difference. In the heart, the peak levels in the ADM group were observed on days 0, 2 and 5. The Co Q₁₀ group showed a statistically significant inhibition of peroxidation on day 0, but not on day 5. In the liver, the peak levels in the ADM group were observed on days 2 and 6. The Co Q₁₀ group showed same, but not statistically significant inhibition of peroxidation. In the kidney, a delayed response in lipid peroxidation levels was observed, with a shoulder on day 2 and a peak on day 4. The Co Q₁₀ group showed a statistically significant inhibitory effect against peroxidation on days 2 and 4. In the spleen, response of the lipid peroxidation levels was slow, and an inhibitory effect of Co Q₁₀ was not observed (Table 2).
<table>
<thead>
<tr>
<th>Plasma or tissues</th>
<th>Days after Co Q₀ or ADM administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Plasma</td>
<td>7.8 ± 2.1</td>
</tr>
<tr>
<td></td>
<td>7.9 ± 1.0</td>
</tr>
<tr>
<td>Liver</td>
<td>112.1 ± 18.6</td>
</tr>
<tr>
<td>ADM alone</td>
<td>185.3 ± 73.4</td>
</tr>
<tr>
<td>ADM + Co Q₀</td>
<td>119.1 ± 24.3</td>
</tr>
<tr>
<td>Heart</td>
<td>190.4 ± 31.2</td>
</tr>
<tr>
<td>ADM alone</td>
<td>82.3 ± 24.1</td>
</tr>
<tr>
<td>ADM + Co Q₀</td>
<td>80.4 ± 10.0</td>
</tr>
<tr>
<td>Kidney</td>
<td>35.9 ± 3.2</td>
</tr>
<tr>
<td>ADM alone</td>
<td>34.9 ± 3.6</td>
</tr>
<tr>
<td>ADM + Co Q₀</td>
<td>35.9 ± 3.2</td>
</tr>
</tbody>
</table>

The values are the mean ± S.D. of duplicate determinations on 6 separate mice. a: Significantly different from the value obtained with ADM alone (b: P < 0.02, c: P < 0.01).
Effect of Co Q₁₀ on ADM-Toxicity

DISCUSSION

Co Q₁₀ showed a protective effect against subacute toxicity induced in mice with an intraperitoneal administration of ADM. Possible mechanisms of the ADM-induced toxicity have been reported to be interference with DNA directed DNA or RNA synthesis (11), inhibition of mitochondrial oxidative phosphorylation (12), inhibition of membrane Na⁺-K⁺-ATPase (13), calcium accumulation in the myocardium (14) and so forth. ADM, an amphiphilic compound, interacts electrostatically with negatively charged lipids, especially cardiolipin (15, 16). ADM has been shown to be distributed in tissues rich in membrane phospholipids, namely, the liver, kidney and heart (17-19), then, to accumulate in these organs (20) and destabilize the cell membrane (21). Therefore, production of lipid peroxidation (22) due to membrane damage was considered to induce toxicity. Co Q₁₀ and α-tocopherol, having free radical scavenger (22, 23) and membrane stabilizing effects (6-8, 24) were expected to have a protective effect against ADM-induced toxicity. The effectiveness of α-tocopherol against ADM-induced toxicity has been found in terms of cardiac function (25), survival (22, 26), and biochemistry (27), but experiments showing no effect also have been reported (8, 28). Several reports have been made on the protective effect of Co Q₁₀ against ADM-induced toxicity (12, 29-33). Yamanaka et al. (32) reported that the plasma levels of lipid peroxidation correlated negatively with the survival time of mice. In our experiments, Co Q₁₀ markedly prolonged the survival time of mice, but did not inhibit lipid peroxidation. Kishi et al. (33) reported that Co Q₁₀ prevented the ADM-induced inhibition of succinoxidase and NADH-oxidase enzymes in the mitochondria. Our findings concerning survival agree with those reported by Kishi et al. from in vitro experiments. Although we examined lipid peroxidation at the tissue homogenate level, further investigation should be done at the mitochondrial and microsomal levels.

Acknowledgement. We thank Dr. T. Fukuda for providing facilities for this work.

REFERENCES


Effect of Co \( \text{Q}_{10} \) on ADM-Toxicity


